よむ、つかう、まなぶ。
参考資料15 COVID-19 vaccine safety update; Primary series in young children and booster doses in older children and adults, ACIP September 1, 2022 (24 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000208910_00052.html |
| 出典情報 | 第85回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、令和４年度第14回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会（合同開催）（10／7）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
VAERS reporting rates of verified myocarditis per 1 million mRNA COVID-19 1st and
2nd booster vaccinations (Pfizer-BioNTech or Moderna), days 0–7 post-vaccination*,†
1st booster (≥5 years)
2nd booster (≥50 years)
Age group
Male
Female
Male
Female
5–11 years
12–15 years
16–17 years
18–24 years
25–29 years
30–39 years
40–49 years
50–64 years
65+ years
0.0
12.9
21.6
13.1
4.4
1.9
0.2
0.4
0.7
0.0
0.7
0.0
0.6
2.2
0.9
0.6
0.1
0.2
0.0
0.0
0.3
0.0
* As of August 18, 2022. Reports verified to meet case definition by provider interview or medical record review.
†
An estimated 1–10 cases of myocarditis per 100,000 person years occurs among people in the United States, regardless of vaccination status; adjusted for days 0–7
risk interval, this estimated background is 0.2 to 2.2 per 1 million person-day 0–7 risk interval (peach shaded cells indicate that reporting rate exceeded estimated
background incidence for the period)
24
2nd booster vaccinations (Pfizer-BioNTech or Moderna), days 0–7 post-vaccination*,†
1st booster (≥5 years)
2nd booster (≥50 years)
Age group
Male
Female
Male
Female
5–11 years
12–15 years
16–17 years
18–24 years
25–29 years
30–39 years
40–49 years
50–64 years
65+ years
0.0
12.9
21.6
13.1
4.4
1.9
0.2
0.4
0.7
0.0
0.7
0.0
0.6
2.2
0.9
0.6
0.1
0.2
0.0
0.0
0.3
0.0
* As of August 18, 2022. Reports verified to meet case definition by provider interview or medical record review.
†
An estimated 1–10 cases of myocarditis per 100,000 person years occurs among people in the United States, regardless of vaccination status; adjusted for days 0–7
risk interval, this estimated background is 0.2 to 2.2 per 1 million person-day 0–7 risk interval (peach shaded cells indicate that reporting rate exceeded estimated
background incidence for the period)
24